Vivani Medical Inc. - Asset Resilience Ratio
Vivani Medical Inc. (VANI) has an Asset Resilience Ratio of 49.91% as of December 2017. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital position of Vivani Medical Inc. to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2017)
This chart shows how Vivani Medical Inc.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Vivani Medical Inc. asset portfolio.
Liquid Assets Composition Over Time
This chart breaks down Vivani Medical Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Vivani Medical Inc. debt and liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $7.24 Million | 49.91% |
| Total Liquid Assets | $7.24 Million | 49.91% |
Asset Resilience Insights
- Very High Liquidity: Vivani Medical Inc. maintains exceptional liquid asset reserves at 49.91% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Vivani Medical Inc. Industry Peers by Asset Resilience Ratio
Compare Vivani Medical Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Vivani Medical Inc. (2012–2017)
The table below shows the annual Asset Resilience Ratio data for Vivani Medical Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 49.91% | $7.24 Million | $14.50 Million | -11.57pp |
| 2016-12-31 | 61.48% | $10.34 Million | $16.81 Million | +5.83pp |
| 2015-12-31 | 55.65% | $15.72 Million | $28.25 Million | -23.29pp |
| 2014-12-31 | 78.94% | $34.00 Million | $43.07 Million | +10.99pp |
| 2013-12-31 | 67.95% | $8.61 Million | $12.67 Million | +14.02pp |
| 2012-12-31 | 53.93% | $4.31 Million | $7.99 Million | -- |
About Vivani Medical Inc.
Vivani Medical, Inc., a clinical-stage biopharmaceutical company, engages in the development of miniaturized and subdermal drug implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the t… Read more